Novartis Everolimus Oral Dosing May Offer Advantages Over Wyeth's Torisel
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Novartis halts Phase III study of the mTOR inhibitor early after everolimus shows better progression-free survival than placebo.
You may also be interested in...
Novartis Speeds RAD001 Filing Schedule After Presenting RECORD-1 At ASCO
With data in hand showing RAD001 (everolimus) doubled progression-free survival in metastatic kidney cancer, Novartis is accelerating its submission schedule and plans to file for the indication by July for a possible 2009 launch of its mTOR inhibitor for oncology
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.